Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450819 | 0.92 | CMA1 (0.67) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL3785099 | 0.91 | CMA1 (0.66) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL3775793 | 0.83 | CMA1 (0.67) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL3785095 | 0.83 | CMA1 (0.67) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL3787960 | 0.82 | CMA1 (0.50) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL7470471 | 0.81 | CMA1 (0.80) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL3786922 | 0.80 | CMA1 (0.69) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL3780426 | 0.79 | CMA1 (0.67) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL3782140 | 0.78 | CMA1 (0.47) | CMA1CA12CA9CA1CA2 | |
| SCHEMBL3782269 | 0.77 | CMA1 (0.69) | CMA1CA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867214-B1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-03-15 | — | — | US | claimed |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1142586-B1 | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-7169951-B2 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1192950-B1 | THERAPEUTIC DRUGS FOR DERMATITIS EXHIBITING A BIPHASIC SKIN REACTION CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-6921766-B1 | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| US-6867214-B1 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| US-6500835-B2 | FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION | SUNTORY LIMITED (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2002-12-05 | — | — | US | disclosed |
| EP-1192949-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192950-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DERMATITISES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1174151-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR VARIOUS EOSINOPHILIA-RELATED DISEASES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1142586-A1 | INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES | SUNTORY LIMITED (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183339-A1 | Medicament for prevention and treatment of dermatitis having chymase inhibitor as effective ingredient | CMA1, SERPINB1, TSLP | CMA1 1/4885CA12 1252/4885CA9 978/4885 |
| US-20050148608-A1 | Quinazoline derivatives and pharmaceutical applications thereof | CMA1, ACE, ACE2 | CMA1 1/4885CA12 999/4885CA9 114/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CMA1 313/4885CA12 4477/4885CA9 4051/4885 |
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | CMA1 1/4885CA12 1154/4885CA9 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.